Clinical trials for professionals
Learn about our available clinical trials



-
January 27, 2023PamplonaIn recruitment
GO43980 Clinical trial to evaluate the safety, pharmacokinetics and activity of XmAb24306 in combination with cevostamab in patients with relapsed/refractory multiple myeloma.
The objective of this study is to evaluate XmAb24306 at different doses to determine whether it is safe in combination with cevostamab and how it is processed by the body. The study will also evaluate cevostamab in monotherapy. -
January 27, 2023MadridIn recruitment
D926UC00001 Trial of datopotamab deruxtecan in monotherapy and in combination with antineoplastic agents in patients with advanced or metastatic solid tumors.
We are conducting this trial to learn more about the drug Datopotomab-Deruxtecan (Dato-DXd) when used alone (monotherapy) and when used with other anticancer drugs (combination treatment). -
January 27, 2023PamplonaIn recruitment
81201887MDG2001 Clinical trial of intravitreal JNJ-81201887 and sham procedure for the treatment of GA secondary to age-related macular degeneration.
The objective of this study is to see if JNJ-81201887 (also called AAVCAGsCD59) is safe and useful for treating patients with geographic atrophy secondary to age-related macular degeneration. -
January 27, 2023PamplonaIn recruitment
AP-325.04 Ensayo clínico para evaluar la eficacia y seguridad de AP-325 en pacientes con dolor neuropático periférico post-quirúrgico
The aim of this study is to investigate whether the newly developed drug AP-325 can reduce neuropathic pain in patients suffering from ongoing neuralgia (neuropathic pain) after breast, thoracic, abdominal, varicose vein, gynecological or inguinal hernia repair surgery. In addition, how each patient tolerates AP-325 will be investigated and the AP-325 blood concentration will be measured. -
January 20, 2023PamplonaIn recruitment
54179060MCL3004 Trial of ibrutinib with rituximab for the treatment of relapsed/refractory mantle cell lymphoma.
The objective of this study is to determine the recommended dose of ibrutinib when administered together with rituximab and to test whether this combination is safe and effective in treating mantle cell lymphoma that has recurred ("relapsed") or was refractory to previous treatment ("refractory"). -
January 20, 2023PamplonaIn recruitment
K36-MMSET-001 Trial of KTX-1001 inhibiting H3K36me2 in patients with relapsed and refractory multiple myeloma.
The aim of this study is to analyze the safety and tolerability of the study drug and to find out how it is processed by the body. -
January 20, 2023MadridIn recruitment
M20-621 Clinical trial of Epcoritamab in combination with R-CHOP compared to R-CHOP in subjects with newly diagnosed Diffuse Large B-Cell Lymphoma. Immunotherapy
The objective of this study is to evaluate the efficacy and safety of the study drug (epcoritamab) when administered in combination with standard treatments, namely R-CHOP (rituximab, cyclophosphamide, oxorubicin, vincristine and prednisone) for newly diagnosed diffuse large B-cell lymphoma (DLBCL). -
January 18, 2023MadridIn recruitment
75348780LYM1001 Clinical trial of JNJ-75348780, an anti-CD3xCD22 bispecific antibody, in subjects with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
The goal of this research study is to find a safe dose of JNJ-75348780 that can be used to treat patients with B-lymphocyte non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Another goal is to find out how long JNJ-75348780 stays and acts in the body and how the body reacts to the drug. -
January 18, 2023PamplonaIn recruitment
PLASFRI-CUV Clinical trial with cold plasma at atmospheric air pressure for the acceleration of venous ulcer healing
The objective of the study is to demonstrate an improvement in the healing time of venous ulcers located in the lower extremities by the application of cold plasma at atmospheric air pressure, using the PlasmAction Med equipment. -
January 18, 2023PamplonaIn recruitment
ANVS-22001 Clinical trial to investigate the efficacy and safety of buntanetap compared to placebo in participants with early PD.
Buntanetap has been shown to reduce the levels of several neurotoxic aggrecan proteins, which are key proteins involved in the progression of Parkinson's disease and other neurodegenerative disorders (a type of disease in which cells in the central nervous system [e.g., the brain] stop functioning). It is believed that buntanetap may improve the current treatment of Parkinson's disease. The goal of this research study is to test whether this study drug (buntanetap) is effective and safe ...